킴스온라인

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

Alzheimer’s Association International Conference 2025 (AAIC 2025)

27 July - 31 July, 2025, Canada

Oral blarcamesine delivers long-term benefit in early AD

2025-11-03

Findings from the phase IIb/III ATTENTION-AD study reflect the continued benefit of oral blarcamesine in individuals with early Alzheimer’s disease (AD) after receiving the drug continuously for up to 4 years.
TRAILBLAZER-ALZ 6 updates support new donanemab dosing schedule for AD

2025-11-03

In the 18-month results from the phase IIIb TRAILBLAZER-ALZ 6 trial, the newly recommended dosing schedule of donanemab results in a significant reduction in the incidence of amyloid-related imaging abnormalities with effusion/oedema (ARIA-E) compared with standard dosing in adults with early symptomatic Alzheimer’s disease (AD).

주요메뉴